Literature DB >> 15667500

Bowel habits in hemorrhoid patients and normal subjects.

Helgi Orn Johannsson1, Wilhelm Graf, Lars Påhlman.   

Abstract

OBJECTIVES: Bleeding, pain, soiling, and prolapse are the classic symptoms in hemorrhoid disease, but the patients sometimes report a variety of other symptoms. Little is known about functional bowel symptoms in patients with hemorrhoids and few studies have previously addressed this subject. The aim of this study was to compare patients with hemorrhoids with a control population regarding functional bowel symptoms and anorectal complaints.
METHODS: One hundred consecutive patients who participated in a randomized study on hemorrhoidectomy completed a validated questionnaire on bowel and anorectal functional symptoms. Two hundred age- and gender-matched population based control subjects, and 100 gender-matched consecutive patients undergoing an orthopedic procedure served as two control groups, and completed the same questionnaire.
RESULTS: Bowel frequency was the same in all three groups, but only 37% of the patients described their bowel movements as normal, compared to 55 and 67% of the controls (p < 0.001). Up to 37% of the patients reported bloating, compared to 18 and 26% in the control groups. Abdominal pain associated with bowel evacuation was experienced by 34% of the patients but in 3 and 5% of the controls (p < 0.001). Excessive straining, feeling of incomplete evacuation, and repeated toilet visits were significantly more usual in the patients. Reduced feeling of well being and disturbed social life caused by bowel symptoms was often reported by patients but rarely in the control groups.
CONCLUSIONS: Beside hemorrhoidal symptoms, many patients with Grade 3-4 hemorrhoids have concomitant functional bowel symptoms, possibly associated with the irritable bowel syndrome. This knowledge might be important while selecting therapy for patients with hemorrhoids.

Entities:  

Mesh:

Year:  2005        PMID: 15667500     DOI: 10.1111/j.1572-0241.2005.40195.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

Review 1.  Controversies in the treatment of common anal problems.

Authors:  Ismail Sagap; Feza-H Remzi
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

2.  [Consensus statement haemorrhoidal disease].

Authors:  Felix Aigner; Friedrich Conrad; Ingrid Haunold; Johann Pfeifer; Andreas Salat; Max Wunderlich; Rene Fortelny; Helga Fritsch; Markus Glöckler; Hubert Hauser; Andreas Heuberger; Judith Karner-Hanusch; Christoph Kopf; Peter Lechner; Stefan Riss; Sebastian Roka; Matthias Scheyer
Journal:  Wien Klin Wochenschr       Date:  2012-03-02       Impact factor: 1.704

3.  Anal Health Care Basics.

Authors:  Jason Chang; Elisabeth Mclemore; Talar Tejirian
Journal:  Perm J       Date:  2016-10-10

4.  Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis.

Authors:  Mehmet Rami Helvaci; Mustafa Cem Algin; Hasan Kaya
Journal:  Eurasian J Med       Date:  2009-12

Review 5.  Rethinking What We Know About Hemorrhoids.

Authors:  Robert S Sandler; Anne F Peery
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-27       Impact factor: 11.382

6.  Risk Factors for Hemorrhoids on Screening Colonoscopy.

Authors:  Anne F Peery; Robert S Sandler; Joseph A Galanko; Robert S Bresalier; Jane C Figueiredo; Dennis J Ahnen; Elizabeth L Barry; John A Baron
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

7.  Chronic Metformin Therapy is Associated with a Lower Risk of Hemorrhoid in Patients with Type 2 Diabetes Mellitus.

Authors:  Chin-Hsiao Tseng
Journal:  Front Pharmacol       Date:  2021-02-16       Impact factor: 5.810

8.  Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial.

Authors:  Steven R Brown; James P Tiernan; Angus J M Watson; Katie Biggs; Neil Shephard; Allan J Wailoo; Mike Bradburn; Abualbishr Alshreef; Daniel Hind
Journal:  Lancet       Date:  2016-05-25       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.